Extended Data Fig. 3: XMV-Ag targets DCs and promotes DC maturation in vivo. | Nature Biomedical Engineering

Extended Data Fig. 3: XMV-Ag targets DCs and promotes DC maturation in vivo.

From: Targeting vaccines to dendritic cells by mimicking the processing and presentation of antigens in xenotransplant rejection

Extended Data Fig. 3

Mice were subcutaneously injected with FITC labeled XMV-Ag at 0 h. After 24 h, the LNs were collected and the percentages of cellular uptake of FITC-XMV-Ag in LNs were determined using flow cytometry. a. Flow cytometry analysis of cellular uptake of XMV-Ag in LNs. Representative flow dot plots (left) and the percentages of XMV-Ag uptake by various cells in LNs (right) are shown. b. Gating strategy for flow cytometry analysis of DC subtypes such as cDC1(CD317-B220-CD11c+MHC-II+XCR1+), cDC2(CD317-B220-CD11c+MHC-II+CD172+) and pDC (CD317+B220+) in LNs. Mice were treated with XMV-Ag for 24 h and the percentages of CD11c+ CD40+ DCs (c) and CD11c+ CD86+ DCs (d) in LNs were determined using flow cytometry. Data are presented as mean ± s.d. Data in a, c-d, n = 3 independent biological samples per group.

Source data

Back to article page